Figure 3.
Figure 3. Outcomes after progression. (A) Outcomes of patients post-CLL progression or RT on venetoclax. Patients are grouped according to histology at progression (progressive CLL, progression with chronic lymphocytic leukemia only). Each patient line begins at time of progression on venetoclax. A light green bar represents time from progression prior to next treatment. Treatment of progression is marked by a red, yellow, or blue bar, representing salvage chemotherapy for RT, or FCR or BTKI therapy for progressive CLL, respectively. (B) Survival of patients whose disease progressed on venetoclax. Data are grouped according to histology at progression and differences are assessed by log-rank testing. TOX, death from toxicity.

Outcomes after progression. (A) Outcomes of patients post-CLL progression or RT on venetoclax. Patients are grouped according to histology at progression (progressive CLL, progression with chronic lymphocytic leukemia only). Each patient line begins at time of progression on venetoclax. A light green bar represents time from progression prior to next treatment. Treatment of progression is marked by a red, yellow, or blue bar, representing salvage chemotherapy for RT, or FCR or BTKI therapy for progressive CLL, respectively. (B) Survival of patients whose disease progressed on venetoclax. Data are grouped according to histology at progression and differences are assessed by log-rank testing. TOX, death from toxicity.

Close Modal

or Create an Account

Close Modal
Close Modal